New patents approved for ColdZyme in Japan and Russia
STOCKHOLM, Sept. 23, 2020 /PRNewswire/ -- The Japanese Patent Office announced that it had granted Enzymatica's patent (6718375) for the cod enzyme which is one of the key components in Enzymatica's ColdZyme® cold spray. The patent includes use of the cod enzyme for treatment and prevention of microbial infections in individuals with immunodeficiency. The patent is valid until 2035. In addition, the Patent Office of the Russian Federation approved a patent in which cod enzymes (trypsin and chymotrypsin) are covered in combination with antibiotics for treatment of streptococcal biofilm in the upper and lower respiratory tract. The patent (2725800) is valid until 2036.
The patent in Japan covers treatment and prevention of microbial infections with ColdZyme in patients with immunodeficiency. Enzymatica has previously conducted a study in which treatment with ColdZyme in a 12-year old boy with primary immunodeficiency showed good results. The patent application is based in part on the results of treatment with ColdZyme, demonstrating a pronounced reduction in the number of infections and symptoms of infection, as well as a sharp reduction in sickness absence during the 15-month treatment period compared with an earlier period of 21 months without treatment. The results of the study were published in the Journal of Medical Case Reports, 20161.
The Patent Office of the Russian Federation approved a patent in which cod enzymes (trypsin and chymotrypsin) are covered in combination therapy with antibiotics to treat bacterial biofilm (Streptococcus mitis and/or Streptococcus pneumoniae) in the upper and lower respiratory tract. The antibiotic in combination therapy may consist of broad-spectrum antibiotics such as tetracycline, cefotaxime, vancomycin, erythromycin or oxacillin.
"We are pleased that Japan and Russia have granted patent approval. The patents enable us to focus on new indications for ColdZyme moving forward, such as upper respiratory tract infections or as part of combination therapy for biofilm, but which would first require additional clinical trials," says Claus Egstrand, Chief Operating Officer för Enzymatica.
1. Clarsund M, Blom U, Gardulf A. Evaluation of ColdZyme® Mouth Spray on prevention of upper respiratory tract infections in a boy with primary immunodeficiency: a case report. Journal of Medical Case Reports. 2016 Oct 31;10(1):302.
FOR MORE INFORMATION PLEASE CONTACT:
Chief Operating Officer
Tel: +44 7780 22 8385
Head of Corporate Communications
Tel: +46 (0)701-88 50 21
About Enzymatica AB
Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company's first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in 15 countries on 3 continents. The strategy is to continue to grow by developing more health care products and strengthening the company's position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases
Enzymatica's certified adviser is Erik Penser Bank. Phone: +46 (0)8 463 83 00. Email: email@example.com
Enzymatica AB Ideon Science Park, SE-223 70 Lund, Sweden Telefon +46 46-286 31 00
This information was brought to you by Cision http://news.cision.com
The following files are available for download: